VIDEO: Momelotinib benefits maintained at 24 weeks in patients with anemic myelofibrosis
Click Here to Manage Email Alerts
NEW ORLEANS — In this video, Aaron T. Gerds, MD, MS, assistant professor at the Cleveland Clinic Taussig Cancer Institute, discusses updated results from the Momentum phase 3 study presented at the ASH Annual Meeting and Exposition.
In the study of momelotinib vs. danazol in symptomatic patients with anemic myelofibrosis previously treated with a JAK inhibitor, patient responses showed benefits of momelotinib therapy continued at week 48.
"What we saw was that patients who had responses at week 24 maintain those through the next 24 weeks in terms of spleen volume response, symptom burden improvement and transfusion independence," Gerds said.
In addition, patients who responded to danazol and who were switched to momelotinib continued to respond.
"Lastly you saw new responses in patients who didn't have a response at week 24 and switched from danazol to momelotinib," Gerds said.
Collapse
Gerds A, et al. Abstract 627. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Read more about
Click Here to Manage Email Alerts